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CASE REPORT Open Access
Spontaneous clearance of hepatitis C virus
after liver transplantation: a report of four
cases
Ichiro Tamaki1, Toshimi Kaido1*, Shintaro Yagi1, Yoshihide Ueda2, Etsuro Hatano1, Hideaki Okajima1
and Shinji Uemoto1
Abstract
End-stage liver disease associated with hepatitis C virus (HCV) infection is the leading indication for liver transplantation.
Hepatitis C virus infection recurrence in the graft is common under immunosuppression, leading to an accelerated rate
of graft failure. We report the clinical features of four of our patients: three patients presenting with spontaneous
hepatitis C virus clearance after liver transplantation and one presenting with transient disappearance of hepatitis C
virus postoperatively. The transitional period from surgery to hepatitis C virus clearance was <5 months for all patients.
The immunosuppression therapy included tacrolimus, mycophenolate mofetil, and corticosteroids. One ABO-
incompatible patient presented spontaneous viral clearance postoperatively for the last 5 years. Two patients
had episodes of severe bacterial infection, which resulted in a temporary reduction of immunosuppression.
Two patients presented with a transient elevation of transaminase preceding spontaneous hepatitis C virus
clearance. These clinical findings suggested that factors including surgical stress, severe bacterial infection, and
temporary interruption of immunosuppression were correlated with the reactivation of nonspecific immune
responses in the hosts, resulting in spontaneous hepatitis C virus clearance postoperatively.
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Background
Hepatitis C virus (HCV) infection-associated end-stage
liver disease is the leading indication for liver transplant-
ation (LT). HCV recurrence in the liver graft is common
when HCV viremia is confirmed during LT, leading to
an accelerated rate of graft failure [1, 2]. In the liver
transplant setting, immunosuppression is an important
determinant for increased HCV replication. Therefore, a
balance between immunosuppression and anti-viral ther-
apies is crucial in the postoperative clinical course [3].
Spontaneous HCV clearance in chronic carriers of the
virus was reportedly consistent in a small post-LT
patient population, although the natural course of HCV
has not been completely elucidated [4, 5]. Furthermore,
spontaneous HCV clearance after LT is rare and few
cases have been reported [2]. Here, we report the clinical
features of four patients, of whom three patients pre-
sented a spontaneous HCV clearance over a short dur-
ation after LT (case 1, case 2, and case 3) and one
presented transient viral disappearance postoperatively
(case 4). These patients were undergoing immunosup-
pression during HCV clearance.
Case presentation
Case 1
A 66-year-old man was admitted to our hospital for a
living donor liver transplantation (LDLT) for HCV-
associated hepatocellular carcinoma (HCC) concomitant
with end-stage liver cirrhosis [Child-Pugh score, 9;
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Model for End-Stage Liver Disease (MELD) score, 21].
Pegylated interferon (PEG-IFN) therapy could not obtain
sustained virologic response 8 years before LT. At ad-
mission, his HCV-RNA level was 5.3 log IU/ml (range
1.2–8.0 log IU/ml) and genotype was 1b. The donor was
ABO incompatible; therefore, plasma exchange and ri-
tuximab administration (300 mg/body weight) were con-
ducted before LT. Postoperative immunosuppression
included tacrolimus (FK506), mycophenolate mofetil
(MMF), and methylprednisolone (MP). Fulminant sepsis
associated with blood stream infection and cholangitis
made the postoperative course complicated. Enterobac-
ter cloacae and Enterococcus faecium were detected from
the blood culture postoperatively. On day 30, serum as-
partate aminotransferase (AST) level increased to
130 U/l, and a liver biopsy was performed. The specimen
revealed cholangitis, although acute cellular rejection
(ACR) was not biologically confirmed [rejection activity
index (RAI) 2]. A similar event was again detected on
day 90. HCV-RNA level decreased to 3.7 log IU/ml on
day 65 and disappeared by day 152. His HCV-RNA
remained undetectable over the last 5 years. To our
knowledge, this is the first case of spontaneous HCV
clearance for an ABO-incompatible LDLT (Table 1)
(Fig. 1).
Case 2
Our second patient was a 61-year-old man who under-
went LDLT for HCV-associated HCC and end-stage liver
cirrhosis (Child-Pugh score, 9; MELD score, 11). His
IFN therapy failed 21 years before LT due to a psycho-
logical side effect. His HCV-RNA level was 2.3 log IU/
ml on admission, and genotype was 2. Severe sepsis oc-
curred on day 13, resulting in a transient reduction of
immunosuppression. Gram-negative rods were detected
in blood, although the origin was not revealed. On day
39, serum AST and alanine aminotransferase (ALT)
levels gradually increased and peaked on day 91 to 416
and 226 U/l, respectively. Liver specimens were taken
three times during this period, revealing neutrophil infil-
tration around the portal area. The diagnosis was mild
rejection (RAI 3) and cholangitis. Six hundred milli-
grams of MP was administered for a treatment of ACR.
On day 112, the HCV-RNA level decreased to
1.2 log IU/ml and disappeared by day 141. His HCV-
RNA remained undetectable over the last 5 years
(Fig. 2).
Case 3
Our third case was a 55-year-old man who underwent
LDLT for HCC and end-stage liver cirrhosis (Child-Pugh
Table 1 Baseline characteristics of the four study patients
Case 1 Case 2 Case 3 Case 4
Age (years) 66 61 55 55
Sex Male Male Male Male
MELD score (points) 21.4 11 33 8
Child-Pugh (score) B (9) B (9) C (13) B (7)
Preoperative HCV-
RNA (log IU/ml)
5.3 2.3 2.1 5.5
HCV treatment status PEG-IFN→ nonresponder
(8 years in advance of LT)
IFN→ terminated due to psychological
side effect (21 years in advance of LT)
IFN → failure (9 years
in advance of LT)
IFN→ nonresponder
(8 years advance of LT)
Genotype 1b 2 1b 1b
Rejection episodes None (RAI 2) Yes (RAI 3) None (RAI 1) Yes (RAI 2)
ABO blood type Incompatible Identical Identical Identical
Immunosuppression Rituximab (preoperatively)
MMF. FK506, MP




152 141 177 14
Re-emergence of
HCV-RNA
None None None Yes (day 85)
Perioperative
morbidity
Sepsis Sepsis ACR, steroid pulse
Follow-up periods
(years)
5 5 9 1
MELD Model for End-Stage Liver Disease, LT liver transplantation, MMF mycophenolate mofetil, FK506 tacrolimus, MP methylprednisolone, PSL prednisolone, ACR
acute cellular rejection
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score, 13; MELD score, 33). IFN therapy failed 9 years
before LT. His HCV-RNA level was 2.1 log IU/ml, and
genotype was 1b. His postoperative course was favorable,
and he was discharged from our hospital at 6 weeks after
operation. On day 22, his serum AST and ALT levels
suddenly increased to 125 and 149 U/l, respectively. A
liver biopsy revealed mild lobular inflammation with no
evidence of rejection (RAI 1). We commenced strong
neo-minophagen C (SNMC) therapy, and the serum
transaminase level decreased to the normal range within
a few days. During the follow-up period, his HCV-RNA
disappeared by day 177 (Fig. 3).
For cases 1, 2, and 3, liver biopsy was performed post-
operatively (range 13 months–5 years). All specimens
represented no finding of hepatic fibrosis or active in-
flammation suggesting active viral hepatitis histologi-
cally. The transaminase level was within normal range in
all of the three patients in the latest blood analysis.
Case 4
Our fourth case was a 55-year-old man who underwent
LDLT for HCV-associated HCC and liver cirrhosis
(Child-Pugh score, 7; MELD score, 8). IFN therapy could
not obtain a sustained virologic response 8 years before
LT. His HCV-RNA level was 5.5 log IU/ml preopera-
tively, and genotype was 1b. Preoperative surveillance re-
vealed cytomegalovirus (CMV) antibody (Ab) and
human T-cell leukemia virus-1 (HTLV-1) Ab. On day 7,
he was diagnosed with ACR because of a sudden eleva-
tion in his white blood cell (WBC) count and serum
transaminase level. He received a 1500-mg MP bolus for
ACR with FK506 and MMF. On day 14 after steroid
pulse therapy, his HCV-RNA decreased below the
threshold range and remission was confirmed on day 30.
During this period, he developed a high fever of un-
detectable origin and was diagnosed with the reactiva-
tion of CMV infection, which was successfully treated
Fig. 1 The clinical course of case 1 who is a 66-year-old male. At admission, his HCV-RNA level was 5.3 log IU/ml. HCV-RNA level decreased to
3.7 log IU/ml on day 65 and disappeared by day 152 and remained undetectable over the last 5 years
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with valganciclovir. In addition, two more adverse events
occurred postoperatively: one was intra-abdominal
bleeding after a liver needle biopsy requiring emergency
surgery, and the other was bacteremia because of ab-
dominal abscess formation. After these problems were
extricated, the re-emergence of HCV-RNA was con-
firmed by HCV-RNA levels of 7.1 log IU/ml on day 85
and 6.1 log IU/ml at 8 months after surgery. We have
been following up the transition of his HCV-RNA very
carefully since then (Fig. 4).
Discussion
Spontaneous HCV clearance from post-LT patients is an
extremely rare phenomenon. For chronic hepatitis C
carriers, spontaneous viral clearance is also considered
to be a rare phenomenon but exists at a constant rate.
Watanabe et al. [4] reported the precise population of
spontaneous HCV clearance from a long-term
population-based cohort study in which 435 HCV carrier
patients were enrolled. He reported that the incidence of
spontaneous viral elimination was 0.5 % per person per
year (3.7 % individuals during the surveillance period).
During January 2005 to December 2014, 156 LT opera-
tions were performed for end-stage liver disease or
HCV-associated HCC in the Kyoto University Hospital.
Three of the patients who presented with postoperative
spontaneous viral clearance accounted for 1.9 % of the
total.
To investigate the relationship between spontaneous
HCV-RNA clearances after LT, we performed a system-
atic review through PubMed (January 2000 to August
2015) that included keywords such as hepatitis C infec-
tion, spontaneous clearance, and LT. We confined the
inclusion criteria to shorter interval periods of ap-
proximately 1 year after LT. Patients who were on
high active anti-retroviral therapy (HAART) for HIV
infection or on IFN and ribavirin (RBV) therapies
were also excluded. HAART was shown as a factor
associated with spontaneous HCV clearance in its nat-
ural course [5].
Fig. 2 The clinical course of case 2 who is a 61-year-old male. At admission, his HCV-RNA level was 2.3 log IU/ml. On day 112, HCV-RNA level
decreased to 1.2 log IU/ml and disappeared by day 141. His HCV-RNA remained undetectable over the last 5 years
Tamaki et al. Surgical Case Reports  (2015) 1:124 Page 4 of 8
This review revealed a small number of patients (n = 8,
including our four cases) in four reports, including the
present case report [2, 6, 7] (Table 2). The population in-
cluded six men and two women aged 32–66 years. Each
patient had the genotype of type 1 (including type 1b in
three patients), two patients had type 2, and one patient
had type 4. Postoperative viral loads were 4.3 ±
1.13 log IU/ml [mean ± standard deviation (SD)]. Focus-
ing on the particular perioperative events, six patients
presented a transient elevation of the serum transamin-
ase level before HCV clearance (AST, 130–532 U/ml;
ALT, 100–540 U/ml; interval periods, 17–280 days).
Four patients had episodes of ACR; several patients
were treated with immunosuppressive agents includ-
ing steroids before HCV clearance. Two of our pa-
tients suffered severe septic complications during
their perioperative periods. HCV clearance was shortly
confirmed after the resolution of these concomitant
problems. These episodes suggest an association be-
tween extraordinary perioperative fluctuations of the
host immunity and viral clearance. Further, over a
natural course of HCV infection, several articles described
spontaneous clearance together with a significant clinical
event such as immune reconstitution after HAART, im-
munosuppressive therapy termination, pregnancy, or
other viral infection onset [8, 9].
In chronic HCV infection, the liver is infiltrated by
mononuclear cells including CD4+, CD8+ T lympho-
cytes, B lymphocytes, natural killer (NK) cells, and NK T
cells [10]. Chronic HCV infection is characterized by an
impaired HCV-specific cytotoxic T lymphocyte (CTL)
response that is unable to control HCV replication [11].
Mutations in the hypervariable region-1 of HCV-
envelope glycoproteins and quasispecies enable HCV to
escape T-cell responses and immunological neutralization
[8, 10]. The mechanism of host immunity restoration
against HCV, which might be a critical part of spon-
taneous HCV clearance, remains unclear. Lauer and
Kim [8] propounded two conceivable scenarios for
improved anti-HCV immunity: one was CD4+ and
CD8+ T-cell reactivation, and the other was a massive
release of type 1 IFN, which activates the dormant
innate immune response. We speculate that factors
including operative physical stress, severe postoperative
Fig. 3 The clinical course of case 3 who is a 55-year-old male. At admission, his HCV-RNA level was 2.1 log IU/ml and disappeared by day 177
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infection, and temporary immunosuppression interrup-
tion were correlated with the reactivation of nonspecific
immune responses. Activation of Toll-like receptors,
which recognize nonspecific molecular structures on
microorganisms and induce type 1 IFN responses, is ex-
pected to be a new therapeutic strategy for chronic
HCV infection [12]. We speculate that a similar mech-
anism explains our findings. Hence, the transient eleva-
tion of transaminase detected before HCV clearance
might reflect the response of CTLs against infected
hepatocytes.
One patient who presented transient viral disappear-
ance had HCV re-emergence immediately following re-
operation and intra-abdominal abscess formation. CMV
reactivation was confirmed at the same time. An inter-
mediate replicative form of the HCV genome can persist
for many years at very low levels in peripheral mono-
nuclear cells after an apparently complete resolution of
chronic hepatitis C [5]. We speculate that further im-
munosuppressive conditions induce HCV re-emergence,
suggesting that the transient disappearance of HCV oc-
curs in more cases. In our clinical practice, we routinely
evaluate the serum HCV-RNA level within a few weeks
after LT.
Conclusions
We reported three cases of spontaneous hepatitis C
virus clearance after liver transplantation and one
presenting with transient disappearance of hepatitis C
virus postoperatively. We believe that an accidental
immunity fluctuation in the hosts resulted in spontan-
eous HCV clearance after LT. Further studies are ne-
cessary to ascertain the factors that may facilitate
HCV clearance.
Consent
Informed consent was obtained from the patients.
The figures related to the article do not contain any
information that may affect the patient’s privacy in
any way.
Fig. 4 The clinical course of case 4 who is a 55-year-old male. His HCV-RNA level was 5.5 log IU/ml preoperatively. On day 14, his HCV-RNA decreased
below the threshold range and remission was confirmed on day 30. The re-emergence of HCV-RNA was confirmed by HCV-RNA levels of 7.1 log IU/ml
on day 85 and 6.1 log IU/ml at 8 months after surgery
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ahead of HCV clearance
Doughty AL
[6] (2000)
49 Male 5.7 N/A N/A Yes MP, AZA, CSA 383 N/A Yes
Elsiesy H
[2] (2015)
32 Female 4.8 4 Failure None FK506, CSA 30 N/A Yes
Kogiso T
[7] (2015)
50 Female 4.3 1 Naïve Yes FK506, MMF, MP, CS 87 ACR Yes
52 Male 4.8 2 Naïve None FK506, MMF, MP, CS 115 N/A Yes
Our cases
Case 1 66 Male 5.3 1b Failure None Rituximab (preoperatively)
FK506, MMF, MP, PSL
152 Sepsis Yes
Case 2 61 Male 2.3 2 Failure Yes FK506, MMF, MP, PSL 111 Sepsis, ACR Yes
Case 3 55 Male 2.1 1b Failure None FK506, MMF, MP, PSL 177 None No
Case 4 55 Male 5.5 1b Failure Yes FK506, MMF, MP, PSL 14 ACR No











Ab: antibody; ACR: acute cellular rejection; ALT: alanine aminotransferase;
AST: aspartate aminotransferase; AZA: azathioprine; CMV: cytomegalovirus;
CSA: cyclosporine; CTLs: cytotoxic T lymphocytes; FK506: tacrolimus;
HAART: high active anti-retroviral therapy; HCC: hepatocellular carcinoma,
HCV, hepatitis C virus; HTLV-1: human T-cell leukemia virus-1; IFN: interferon;
LDLT: living donor liver transplantation; LT: liver transplantation; MELD: Model
for End-Stage Liver Disease; MMF: mycophenolate mofetil;
MP: methylprednisolone; N/A: not available/data not reported;
PSL: prednisolone; RAI: rejection activity index; RBV: ribavirin; SD: standard
deviation; SNMC: strong neo-minophagen C; VGCV: valganciclovir;
WBC: white blood cell.
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